Stock Taper Implemented Providers: Grew to 5,380, a 12.3% increase year-over-year.
Patient Reach: Over 5.8 million patients cared for.
Value-Based Attributed Lives: Increased by 22.7% to 1.54 million.
Practice Collections: Reached $3.47 billion, up 16.9% for the year; Q4 collections were $868.7 million, up 9.6% year-over-year.
Adjusted EBITDA: Increased 38.8% to $125.5 million for the year; Q4 adjusted EBITDA was $31.5 million, representing a 27% EBITDA margin.
Cash Position: Ended the year with $479.7 million in cash, with expectations to reach approximately $600 million by the end of 2026.
EBITDA to Free Cash Flow Conversion: Achieved 130% in 2025; guidance for 2026 is 80%.
Acquisition of Evolent Health's ACO Business: Completed in December, adding over 120,000 value-based attributed lives and expanding into Arizona.
Provider Retention: High gross provider retention rate of 98% and a patient NPS of 87.
Technology Investments: Focus on AI and tech enhancements to improve operational efficiency and patient care delivery.
Sales Momentum: Strong sales activity in Arizona and continued provider growth across existing markets.
2026 Guidance:
Implemented providers expected to grow by 10.6%.
Attributed lives projected to reach approximately 1.58 million.
Practice collections anticipated to grow by 6.6% and care margin by 13%.
Adjusted EBITDA growth expected at approximately 20% to reach $150 million.
Business Development: Plans to remain disciplined in capital deployment while actively seeking growth opportunities.
Slight Decline in Practice Collections: Noted a 40 basis point decline from Q3 to Q4, raising questions about sustainability.
Competitive Pressures: Competitors are beginning to adopt similar risk-sharing models, which could impact provider recruitment and market dynamics.
Regulatory Environment: Changes in ACA and Medicaid enrollment may lead to increased churn and impact utilization trends.
Market Variability: Some markets are still underperforming, and there is a cautious approach to new market entries.
AI Investments: Discussed the integration of AI into various operational aspects, including patient engagement and clinical decision support, with expectations for significant productivity enhancements.
Evolent Acquisition: Management emphasized a cautious approach to integrating the Evolent business, focusing on maintaining existing operations while gradually implementing Privia's practices.
Utilization Trends: Management expressed confidence in maintaining elevated ambulatory utilization, despite potential fluctuations in the ACA and Medicaid populations.
Capital Deployment Strategy: Emphasized the importance of quality over quantity in acquisitions, with a focus on integrating and improving acquired assets. Overall, Privia Health Group demonstrated strong financial performance in 2025, with a solid outlook for 2026, while also acknowledging competitive and regulatory challenges ahead.
SOURCE: Q4 2025 EARNINGS CALL TRANSCRIPT